New Zealand markets open in 5 hours 2 minutes

RemeGen Co Ltd (REG.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
2.4800-0.0400 (-1.59%)
As of 08:08AM CET. Market open.
Full screen
Previous close2.5200
Open2.5200
Bid2.4200 x N/A
Ask2.5800 x N/A
Day's range2.4800 - 2.4800
52-week range1.8600 - 6.5000
Volume592
Avg. volume42
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • PR Newswire

    World Cancer Day 2024: RemeGen Announces Three Significant Developments in the Global Fight Against Cancer, Narrowing the Care Gap

    RemeGen Co. Ltd.("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, with a mission that is closely aligned with the Close the Care Gap theme of World Cancer Day 2024 which falls on February 4, has announced three major developments that will further the global fight against cancer and forge new paths in tumor treatments. The Company not only endeavors to contribute to the field of anti-cancer treatments, but also provide much-improved medical opportunitie

  • PR Newswire

    RemeGen's RC88 Obtained FDA Fast Track Designation, Heralds New Hope for Ovarian Cancer Patients

    RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, announced recently that its independently developed mesothelin (MSLN)-targeting antibody-drug conjugate (ADC), RC88, has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) for the treatment of platinum-resistant recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers. This marks another significant development following the FDA's

  • PR Newswire

    RemeGen's Pioneering RC88 Receives IND Approval from US FDA for Platinum-Resistant Recurrent Ovarian Cancer Treatment

    RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, announced that its independently developed mesothelin-targeting antibody-drug conjugate (ADC), RC88, has recently received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) for Phase II clinical trials in the treatment of gynecological tumors. The company is poised to launch international multicenter clinical studies in the United States, China, the